Cold Application and Exercise on Development of Peripheral Neuropathy during Taxane Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial
- PMID: 33850959
- PMCID: PMC8030600
- DOI: 10.4103/apjon.apjon-2075
Cold Application and Exercise on Development of Peripheral Neuropathy during Taxane Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial
Abstract
Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. There is no proven pharmacological application to prevent CIPN. This study was conducted to compare the effects of cold application and exercise on peripheral neuropathy development in patients with breast cancer who received taxane.
Methods: This was a multicenter clinical trial. The study was conducted as a randomized controlled trial on breast cancer patients who had chemotherapy-induced peripheral neuropathy complaints between July 2017 and January 2018 in an outpatient chemotherapy unit of training-research and a university hospital. A standardized, home-based, 12-week exercise program involved progressive strengthening, stretching, and balance exercises. Cold packs were applied for the duration of all 12 taxane infusions and then continued at home. The standard care protocol (information about side effects) of the clinic was used for patients in the control group. Data were collected via Patient Identification Form and CIPN Assessment Tool. Demographic data were evaluated by number and percentage ratios, and the study groups' mean scores were compared by Kruskal-Wallis and Wilcoxon analyses. The data were collected at two time points including baseline (T1) and week 12 (T2).
Results: The study was completed with a total of 90 patients, so that each of the study groups, exercise, cold application, and control groups, included 30 patients. The mean of pre- and posttest results in the cold applied group revealed an increase in hand numbness, weakness, and distress (P < 0.05). However, no significant difference existed between the means of the pre- and the posttests in the exercise group (P = 0.79-0.1). The mean scores of all the symptoms in the control group except the loss of balance increased significantly (P < 0.05). Exercise reduced CIPN symptoms of numbness in hands (P = 0.009) and in the feet (P = 0.005) significantly compared to the cold application and control.
Conclusions: It was found that exercise was more effective than cold application in the management of CIPN.
Keywords: Cancer; cold application; exercise; nursing; peripheral neuropathy.
Copyright: © 2021 Ann & Joshua Medical Publishing Co. Ltd.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.Support Care Cancer. 2018 Apr;26(4):1019-1028. doi: 10.1007/s00520-017-4013-0. Epub 2017 Dec 14. Support Care Cancer. 2018. PMID: 29243164 Free PMC article. Clinical Trial.
-
Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial.Trials. 2022 Apr 27;23(1):363. doi: 10.1186/s13063-022-06294-w. Trials. 2022. PMID: 35477489 Free PMC article.
-
Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.Clin Breast Cancer. 2019 Dec;19(6):411-422. doi: 10.1016/j.clbc.2019.05.013. Epub 2019 Jun 27. Clin Breast Cancer. 2019. PMID: 31601479 Clinical Trial.
-
Psychological distress and quality of life in breast cancer survivors with taxane-induced peripheral neuropathy: A scoping review.Front Oncol. 2023 Jan 10;12:1005083. doi: 10.3389/fonc.2022.1005083. eCollection 2022. Front Oncol. 2023. PMID: 36703798 Free PMC article.
-
Exercise Effects on Chemotherapy-Induced Peripheral Neuropathy: A Comprehensive Integrative Review.Cancer Nurs. 2020 May/Jun;43(3):E172-E185. doi: 10.1097/NCC.0000000000000801. Cancer Nurs. 2020. PMID: 32187026 Review.
Cited by
-
Striding beyond numbness: a non-randomized controlled study of an exercise program for breast cancer patients with chemotherapy-induced peripheral neuropathy.Support Care Cancer. 2024 Nov 29;32(12):837. doi: 10.1007/s00520-024-09003-2. Support Care Cancer. 2024. PMID: 39611862 Clinical Trial.
-
Exercise intervention for the management of chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis.Front Neurol. 2024 Jan 30;15:1346099. doi: 10.3389/fneur.2024.1346099. eCollection 2024. Front Neurol. 2024. PMID: 38352137 Free PMC article.
-
The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).Support Care Cancer. 2022 Jun;30(6):5509-5517. doi: 10.1007/s00520-022-06975-x. Epub 2022 Mar 21. Support Care Cancer. 2022. PMID: 35312857 Free PMC article. Clinical Trial.
-
Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion.Expert Rev Neurother. 2022 Jan;22(1):65-76. doi: 10.1080/14737175.2022.2018300. Epub 2022 Jan 11. Expert Rev Neurother. 2022. PMID: 34894974 Free PMC article.
-
Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review.Healthcare (Basel). 2023 May 29;11(11):1588. doi: 10.3390/healthcare11111588. Healthcare (Basel). 2023. PMID: 37297728 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–70. - PubMed
-
- Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer. 2010;46:479–94. - PubMed
-
- Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study) Support Care Cancer. 2009;17:1071–80. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources